Canagliflozin (第二型糖尿病治療藥物):開發平台分析及市場預測

本報告提供第2型糖尿病 Canagliflozin 的開發平台評估及市場預測，以市場特徵為首，評估分析競爭，開發平台等，再加上未來市場競爭等資訊，為您概述為以下內容。

1 目錄

1 目錄

• 1.1 表格一覽
• 1.2 圖表一覽

2 簡介

• 2.1 糖尿病
• 2.2 免疫學
• 2.2.1 患病率
• 2.2.2 死亡率
• 2.3 病因及危險因素
• 2.3.1 肥胖症
• 2.3.2 久坐的生活方式
• 2.3.3 家族病史及遺傳的特質
• 2.3.4 民族性
• 2.3.5 老年
• 2.4 經濟影響; 糖尿病
• 2.5 GlobalData 報告指南

3 第二型糖尿病: 市場特性

• 3.1 第二型糖尿病市場
• 3.2 第二型糖尿病市場 預測
• 3.3 第二型糖尿病市場: 促進成長要素及阻礙因素
• 3.3.1 促進成長要素;
• 3.3.2 阻礙因素

4 分類; 糖尿病

• 4.1 類型;糖尿病
• 4.1.1 第一型糖尿病
• 4.1.2 第二型糖尿病
• 4.1.3 妊娠性糖尿病
• 4.2 糖尿病 併發症
• 4.2.1 循環系統疾病
• 4.2.2 腎臟病
• 4.2.3 精神障礙
• 4.2.4 切除手術
• 4.2.5 視網膜症

5 進步; 抗糖尿病治療

6 治療藥物

• 6.1 胰島素
• 6.2 口服治療藥物
• 6.2.1 磺醯尿素類 (SUR)
• 6.2.2 雙胍類 (BGDs)
• 6.2.3 甲型糖解酵素抑制劑 (AGI)
• 6.2.4 Meglitinides
• 6.2.5 Thiozolidinediones (TZDs)
• 6.2.6 DDP-4(DPP- 4) 抑制劑
• 6.2.7 口服並用療法
• 6.3 其他可注射藥物
• 6.3.1 Pramlintide
• 6.3.2 Exenatide
• 6.4 市場佔有率 (每一級) - 第二型糖尿病

7 Canagliflozin

• 7.1 簡介
• 7.2 作用機制
• 7.3 臨床研究
• 7.3.1 第2階段實驗 Canagliflozin Januvia 比較評估(NIDDM 患者的治療)
• 7.3.2 第3階段臨床實驗實驗 有效性, 安全性 及耐藥性比較評估 ; Canagliflozin Amaryl ( 第二型糖尿病治療)
• 7.3.3 第3階段臨床實驗實驗 單劑治療的 Canagliflozin 評估 - 第二型糖尿病 胰島素非依存型糖尿病 患者
• 7.4 銷售額影響因素; Canagliflozin
• 7.4.1 SGLT2 抑制劑 出現
• 7.4.2 體重沒有增加
• 7.5 醫藥品評估
• 7.5.1 藥物的風險·效益評估
• 7.5.2 競爭的激烈程度
• 7.6 銷售額 預測
• 7.6.1 投藥
• 7.6.2 市場滲透率
• 7.6.3 治療的年度成本
• 7.6.4 銷售額預測; Canagliflozin

8 糖尿病市場: 附錄

• 8.1 市場定義
• 8.2 簡稱一覽
• 8.3 調查方法
• 8.3.1 調查範圍
• 8.3.2 二級研究
• 8.3.3 預測
• 8.3.4 核准服藥的患者人數
• 8.3.5 治療藥物的淨市場滲透率
• 8.3.6 年度淨用藥量
• 8.3.7 治療的年度成本
• 8.4 治療藥物的銷售額預期模式
• 8.5 諮詢方式
• 8.6 免責聲明
• 8.7 資訊來源

表格一覽

1.1 表格一覽

• 表格 1: 糖尿病, 全球估計患者數 (20∼79歲的年齡群) (100萬人), 實際成果及預測
• 表格 2: 糖尿病, 前十名國家, 各患者數(100萬人), 實際成果及預測
• 表格 3: 糖尿病, 前十名國家, 最高醫療費 ($bn)
• 表格 4: 第二型糖尿病, 全球各銷售額主要上市藥 ($m)
• 表格 5: 第二型糖尿病, 全球主要 開發中產品 - 第3階段實驗
• 表格 6: 糖尿病, 全球整體, 估計患者數, 實際成果及預測
• 表格 7: 肥胖率, 全球整體, 估計患者數 - 15歲以上的男性 (%)
• 表格 8: 糖尿病 治療藥物的演變
• 表格 9: 藥物的風險·效益評估 (DRB), Canagliflozin
• 表格 10: Canagliflozin, 第二型糖尿病, 全球整體, 銷售額 預測 ($m)
• 表格 11: Canagliflozin, 第二型糖尿病, 美國, 銷售額 預測 ($m)
• 表格 12: Canagliflozin, 第二型糖尿病, 英國, 銷售額 預測 ($m)
• 表格 13: Canagliflozin, 第二型糖尿病, 法國, 銷售額 預測 ($m)
• 表格 14: Canagliflozin, 第二型糖尿病, 德國, 銷售額 預測 ($m)
• 表格 15: Canagliflozin, 第二型糖尿病, 義大利, 銷售額 預測 ($m)
• 表格 16: Canagliflozin, 第二型糖尿病, 西班牙, 銷售額 預測 ($m)
• 表格 17: Canagliflozin, 第二型糖尿病, 日本, 銷售額 預測 ($m)

圖表一覽

1.2 圖表一覽

• 圖 1: 糖尿病, 全球患病率比較 - 20∼79歲的年齡群 (%)
• 圖 2: 糖尿病, 全球患病率比較 - 20∼79歲的年齡群 (%), 預測
• 圖 3: 糖尿病, 全球死亡率
• 圖 4: 全球10大死因
• 圖 5: 第二型糖尿病, 全球整體, 市場規模預測 ($bn)，預測
• 圖 6: 作用機制 ; 磺醯尿素類
• 圖 7: 作用機制 ; Biguanide, Thiozolidinediones, 甲型糖解酵素抑制劑
• 圖 8: 作用機制 ; metohorumin 及 甲型糖解酵素抑制劑
• 圖 9: 作用機制 ; Thiozolidinediones
• 圖 10: 作用機制 ; DPP IV 抑制劑
• 圖 11: 第二型糖尿病, 全球整體, 各銷售額市場佔有率, 各級 (%)
• 圖 12: Canagliflozin, 第二型糖尿病, 全球整體, 銷售額 預測 ($m)
• 圖 13: Canagliflozin, 第二型糖尿病, 美國, 銷售額 預測 ($m)
• 圖 14: Canagliflozin, 第二型糖尿病, 英國, 銷售額 預測 ($m)
• 圖 15: Canagliflozin, 第二型糖尿病, 法國, 銷售額 預測 ($m)
• 圖 16: Canagliflozin, 第二型糖尿病, 德國, 銷售額 預測 ($m)
• 圖 17: Canagliflozin, 第二型糖尿病, 義大利, 銷售額 預測 ($m)
• 圖 18: Canagliflozin, 第二型糖尿病, 西班牙, 銷售額 預測 ($m)
• 圖 19: Canagliflozin, 第二型糖尿病, 日本, 銷售額 預測 ($m)
• 圖 20: Canagliflozin, 第二型糖尿病, 各國銷售額分佈 (%), 預測
• 圖 21: 服用這種藥物的患者

Abstract

Canagliflozin (Type 2 Diabetes) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Canagliflozin (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Canagliflozin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

• Therapy area profile including patient population for the US, EU% and Japan (seven major markets)
• Analysis and review of Canagliflozin
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Canagliflozin including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2013-2020 for Canagliflozin in the US, EU5 and Japan

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug's performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

TOC

1 Table of Contents

1 Table of Contents 2

• 1.1 List of Tables 4
• 1.2 List of Figures 4

2 Introduction 5

• 2.1 Diabetes 5
• 2.2 Epidemiology 5
• 2.2.1 Prevalence 5
• 2.2.2 Mortality 7
• 2.3 Etiology and Risk Factors 9
• 2.3.1 Obesity 9
• 2.3.2 Sedentary Lifestyle 9
• 2.3.3 Family History and Genetics 9
• 2.3.4 Ethnicity 9
• 2.3.5 Old Age 9
• 2.4 Economic Impact of Diabetes 9
• 2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

• 3.1 Type 2 Diabetes Market 12
• 3.2 Type 2 Diabetes Market Forecasts 13
• 3.3 Type 2 Diabetes Market: Drivers and Restraints 14
• 3.3.1 Drivers 14
• 3.3.2 Restraints 15

4 Classification of Diabetes 16

• 4.1 Types of Diabetes 16
• 4.1.1 Type 1 Diabetes 16
• 4.1.2 Type 2 Diabetes 16
• 4.1.3 Gestational Diabetes 16
• 4.2 Diabetes Complications 16
• 4.2.1 Cardiovascular Disease 16
• 4.2.2 Nephropathy 17
• 4.2.3 Neuropathy 17
• 4.2.4 Amputation 17
• 4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

• 6.1 Insulin 19
• 6.2 Oral Medications 19
• 6.2.1 Sulfonylureas (SUR) 19
• 6.2.2 Biguanides (BGDs) 20
• 6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
• 6.2.4 Meglitinides 21
• 6.2.5 Thiozolidinediones (TZDs) 22
• 6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
• 6.2.7 Oral Combination Therapy 23
• 6.3 Other Injectionable Medications 24
• 6.3.1 Pramlintide 24
• 6.3.2 Exenatide 24
• 6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Canagliflozin 25

• 7.1 Introduction 25
• 7.2 Mechanism of Action 25
• 7.3 Clinical Studies 25
• 7.3.1 A Phase II Trial Evaluating Canagliflozin Vs Januvia for the Treatment of NIDDM Patients 25
• 7.3.2 A Phase III Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Canagliflozin Compared with Amaryl for the Treatment of Type 2 Diabetes 25
• 7.3.3 A Phase III Clinical Trial Evaluating Canagliflozin as a Monotherapy in Type 2 Diabetes Non Insulin Diabetes Mellitus Patients 26
• 7.4 Factors Affecting Sales of Canagliflozin 26
• 7.4.1 Emergence of SGLT2 inhibitors 26
• 7.4.2 No Weight Gain 26
• 7.5 Drug Evaluation 26
• 7.5.1 Drug Risk Benefit Score 26
• 7.5.2 Intensity of Competition 27
• 7.6 Sales Forecasts 28
• 7.6.1 Dosing 28
• 7.6.2 Market Penetration 28
• 7.6.3 Annual Cost of Therapy 28
• 7.6.4 Sales Projections of Canagliflozin 29

8 Diabetes Market: Appendix 38

• 8.1 Market Definitions 38
• 8.2 List of Abberiviations 38
• 8.3 Research Methodology 38
• 8.3.1 Coverage 39
• 8.3.2 Secondary Research 39
• 8.3.3 Forecasting 39
• 8.3.4 Number of patients approved to take the drug 39
• 8.3.5 Net Penetration of Drug 40
• 8.3.6 Net Annual Dosing 40
• 8.3.7 Annual Cost of Therapy 40
• 8.4 Drug Sales Estimates Model 40
• 8.5 Contact Us 40
• 8.6 Disclaimer 41
• 8.7 Sources 41

List of Tables

1.1 List of Tables

• Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
• Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
• Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
• Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010 12
• Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trails 13
• Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
• Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
• Table 8: Diabetes Drugs Evolution 18
• Table 9: Drug Risk Benefit Score (DRB), Canagliflozin 26
• Table 10: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013-2020 29
• Table 11: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013-2020 30
• Table 12: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013-2020 31
• Table 13: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2013-2020 32
• Table 14: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013-2020 33
• Table 15: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013-2020 34
• Table 16: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013-2020 35
• Table 17: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016-2020 36

List of Figures

1.2 List of Figures

• Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
• Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
• Figure 3: Diabetes, World, Mortality, 2010 7
• Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
• Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020 13
• Figure 6: Mechanism of Action of Sulfonylureas 19
• Figure 7: Mechanism of Action of Biguanide, Thiozolidinediones, Alpha-Glucosidase Inhibitors 20
• Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
• Figure 9: Mechanism of Action of Thiozolidinediones 22
• Figure 10: Mechanism of Action of DPP IV Inhibitors 23
• Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
• Figure 12: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013-2020 29
• Figure 13: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013-2020 30
• Figure 14: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013-2020 31
• Figure 15: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2013-2020 32
• Figure 16: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013-2020 33
• Figure 17: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013-2020 34
• Figure 18: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013-2020 35
• Figure 19: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016-2020 36
• Figure 20: Canagliflozin, Type 2 Diabetes, Sales Distribution by Country (%), 2020 37
• Figure 21: Patients Approved for the Drug 40